We hope
to gain further insights into the underlying genetic causes and
disease mechanisms of Parkinson's disease, which may be
translated into the development of new targeted therapies for
Parkinson's disease in the future.
Uncovering the roots
of Parkinson's disease, together
of Parkinson's disease, together
We hope to gain further insights
into the underlying genetic causes and disease mechanisms of Parkinson's disease, which may be translated into the development of new targeted therapies for Parkinson's disease in the future.
into the underlying genetic causes and disease mechanisms of Parkinson's disease, which may be translated into the development of new targeted therapies for Parkinson's disease in the future.
What are our goals?
This is an opportunity to better understand the genetic
architecture of Parkinson's disease in your country,
as all recruited patients will undergo extensive genotyping including testing for known mutations
in established Parkinson's disease genes, as well as whole genome sequencing and/or long-read sequencing in a selection of patients/families.
We encourage the submission of both patients without a genetic diagnosis and those already known to carry pathogenic variants in Parkinson's disease genes.
To submit a patient/family, go to
as all recruited patients will undergo extensive genotyping including testing for known mutations
in established Parkinson's disease genes, as well as whole genome sequencing and/or long-read sequencing in a selection of patients/families.
We encourage the submission of both patients without a genetic diagnosis and those already known to carry pathogenic variants in Parkinson's disease genes.
To submit a patient/family, go to
The two major aims of GP2 are to discover novel
genetic causes of Parkinson's disease and to better characterize
modifying factors influencing disease
manifestation and progression.
To address these aims, the Monogenic Hub will recruit
and investigate Parkinson's disease patients with a potential monogenic basis, e.g. those with early onset (<50 years), positive family history, or atypical clinical presentation,
with particular attention to those originating from less well
studied (underrepresented) populations.
To address these aims, the Monogenic Hub will recruit
and investigate Parkinson's disease patients with a potential monogenic basis, e.g. those with early onset (<50 years), positive family history, or atypical clinical presentation,
with particular attention to those originating from less well
studied (underrepresented) populations.
This is an opportunity to better understand the genetic
architecture of Parkinson's disease in your country, as all
recruited patients will undergo extensive genotyping including
an testing for known mutations in established Parkinson's disease genes, as well as whole genome sequencing
and/or long-read sequencing in a selection of patients/families.
We encourage the submission of both patients without a genetic diagnosis and those already known to carry pathogenic variants in Parkinson's disease genes.
To submit a patient/family, go to
an testing for known mutations in established Parkinson's disease genes, as well as whole genome sequencing
and/or long-read sequencing in a selection of patients/families.
We encourage the submission of both patients without a genetic diagnosis and those already known to carry pathogenic variants in Parkinson's disease genes.
To submit a patient/family, go to
For clinicians and researchers, this project provides a great
opportunity to better understand the genetic
architecture of PD
in their respective communities/countries,
in addition to opportunities for scientific collaborations and joint publications
and grants.
We encourage the submission of both patients without a genetic diagnosis and those already known to carry pathogenic variants
in Parkinson's disease genes .
To submit a patient/family, go to
in their respective communities/countries,
in addition to opportunities for scientific collaborations and joint publications
and grants.
We encourage the submission of both patients without a genetic diagnosis and those already known to carry pathogenic variants
in Parkinson's disease genes .
To submit a patient/family, go to
We encourage the submission of both patients
without a genetic diagnosis and those already known to carry
pathogenic variants in Parkinson's disease genes.
To submit a patient/family, go to
To submit a patient/family, go to
The two major aims of GP2
are to discover novel genetic causes
of Parkinson's disease and to better characterize modifying factors influencing disease manifestation
and progression.
To address these aims, the Monogenic Hub will recruit and investigate Parkinson's disease patients
with a potential monogenic basis, e.g. those with early onset (<50 years), positive family history, or atypical clinical presentation, with particular attention
to those originating from less well
studied (underrepresented) populations.
are to discover novel genetic causes
of Parkinson's disease and to better characterize modifying factors influencing disease manifestation
and progression.
To address these aims, the Monogenic Hub will recruit and investigate Parkinson's disease patients
with a potential monogenic basis, e.g. those with early onset (<50 years), positive family history, or atypical clinical presentation, with particular attention
to those originating from less well
studied (underrepresented) populations.
The two major aims of GP2 are to discover novel
genetic causes of Parkinson's disease and to better characterize
modifying factors influencing disease
manifestation and progression.
To address these aims, the Monogenic Hub will recruit and investigate Parkinson's disease patients
with a potential monogenic basis, e.g. those with early onset (<50 years), positive family history, or atypical clinical presentation, with particular attention to those originating from less well studied (underrepresented) populations.
To address these aims, the Monogenic Hub will recruit and investigate Parkinson's disease patients
with a potential monogenic basis, e.g. those with early onset (<50 years), positive family history, or atypical clinical presentation, with particular attention to those originating from less well studied (underrepresented) populations.
The two major aims of GP2 are to discover novel
genetic causes of Parkinson's disease and to better characterize
modifying factors influencing disease
manifestation and progression.
To address these aims, the Monogenic Hub will recruit and investigate Parkinson's disease patients
with a potential monogenic basis, e.g. those with early onset (<50 years), positive family history, or atypical clinical presentation, with particular attention
to those originating from less well studied(underrepresented) populations.
This is an opportunity to better understand the genetic architecture of Parkinson's disease in your country,
as all recruited patients will undergo extensive genotyping including an testing for known mutations
in established Parkinson's disease genes,
as well as whole genome sequencing and/or long-read sequencing in a selection of patients/families.
We encourage the submission of both patients without a genetic diagnosis and those already known to carry pathogenic variants in Parkinson's disease genes.
To submit a patient/family, go to
To address these aims, the Monogenic Hub will recruit and investigate Parkinson's disease patients
with a potential monogenic basis, e.g. those with early onset (<50 years), positive family history, or atypical clinical presentation, with particular attention
to those originating from less well studied(underrepresented) populations.
This is an opportunity to better understand the genetic architecture of Parkinson's disease in your country,
as all recruited patients will undergo extensive genotyping including an testing for known mutations
in established Parkinson's disease genes,
as well as whole genome sequencing and/or long-read sequencing in a selection of patients/families.
We encourage the submission of both patients without a genetic diagnosis and those already known to carry pathogenic variants in Parkinson's disease genes.
To submit a patient/family, go to
What are the benefits of contributing cases/families?
For patients, knowledge of one's genetic status can provide valuable
information regarding prognosis (likelihood of developing, or
passing on, the disease; disease course; etc.), which may be helpful
in life planning. It also opens up the possibility
of participating in clinical trials or benefiting from new genetics-based treatments.
Notably, all recruited patients will undergo extensive genotyping including testing for known mutations
in established Parkinson's disease genes (using
the Genome Diversity Array, GDA), and a large proportion will also undergo whole genome
and/or long-read sequencing.
of participating in clinical trials or benefiting from new genetics-based treatments.
Notably, all recruited patients will undergo extensive genotyping including testing for known mutations
in established Parkinson's disease genes (using
the Genome Diversity Array, GDA), and a large proportion will also undergo whole genome
and/or long-read sequencing.
For patients, knowledge of one's genetic status can provide valuable
information regarding prognosis (likelihood of developing, or
passing on, the disease; disease course; etc.), which may be helpful
in life planning.
It also opens up the possibility of participating in clinical trials or benefiting from new genetics-based treatments.
Notably, all recruited patients will undergo extensive genotyping including testing
for known mutations in established Parkinson's disease genes (using the Genome Diversity Array, GDA), and a large proportion will also undergo whole genome
and/or long-read sequencing.
It also opens up the possibility of participating in clinical trials or benefiting from new genetics-based treatments.
Notably, all recruited patients will undergo extensive genotyping including testing
for known mutations in established Parkinson's disease genes (using the Genome Diversity Array, GDA), and a large proportion will also undergo whole genome
and/or long-read sequencing.
For patients, knowledge of one's genetic status can provide valuable
information regarding prognosis (likelihood
of developing, or passing on, the disease; disease course; etc.), which may be helpful in life planning. It also opens up
the possibility of participating in clinical trials or benefiting
from new genetics-based treatments.
Notably, all recruited patients will undergo extensive genotyping including testing for known mutations in established Parkinson's disease genes (using the Genome Diversity Array, GDA),
and a large proportion will also undergo whole genome
and/or long-read sequencing.
For clinicians and researchers, this project provides a great opportunity to better understand the genetic architecture of PD in their respective communities/countries, in addition
to opportunities for scientific collaborations and joint publications and grants.
of developing, or passing on, the disease; disease course; etc.), which may be helpful in life planning. It also opens up
the possibility of participating in clinical trials or benefiting
from new genetics-based treatments.
Notably, all recruited patients will undergo extensive genotyping including testing for known mutations in established Parkinson's disease genes (using the Genome Diversity Array, GDA),
and a large proportion will also undergo whole genome
and/or long-read sequencing.
For clinicians and researchers, this project provides a great opportunity to better understand the genetic architecture of PD in their respective communities/countries, in addition
to opportunities for scientific collaborations and joint publications and grants.
For patients, knowledge of one's genetic status can provide valuable
information regarding prognosis (likelihood of developing, or
passing on, the disease; disease course; etc.), which may be helpful
in life planning. It also opens up the possibility
of participating in clinical trials or benefiting
from new genetics-based treatments.
Notably, all recruited patients will undergo extensive genotyping including testing for known mutations in established Parkinson's disease genes (using the Genome Diversity Array, GDA),
and a large proportion will also undergo whole genome and/or long-read sequencing.
of participating in clinical trials or benefiting
from new genetics-based treatments.
Notably, all recruited patients will undergo extensive genotyping including testing for known mutations in established Parkinson's disease genes (using the Genome Diversity Array, GDA),
and a large proportion will also undergo whole genome and/or long-read sequencing.
The two major aims of GP2 are to discover novel
genetic causes of Parkinson's disease and to better characterize
modifying factors influencing disease
manifestation
and progression.
To address these aims, the Monogenic Hub will recruit and investigate Parkinson's disease patients with a potential monogenic basis, e.g. those with early onset (<50 years), positive family history, or atypical clinical presentation, with particular attention
to those originating from less well studied (underrepresented) populations.
and progression.
To address these aims, the Monogenic Hub will recruit and investigate Parkinson's disease patients with a potential monogenic basis, e.g. those with early onset (<50 years), positive family history, or atypical clinical presentation, with particular attention
to those originating from less well studied (underrepresented) populations.
The two major aims of GP2 are to discover novel
genetic causes of Parkinson's disease and to better characterize
modifying factors influencing disease
manifestation and progression.
To address these aims, the Monogenic Hub will recruit and investigate Parkinson's disease patients with a potential monogenic basis, e.g. those
with early onset (<50 years), positive family history, or atypical clinical presentation, with particular attention to those originating from less well studied (underrepresented) populations.
To address these aims, the Monogenic Hub will recruit and investigate Parkinson's disease patients with a potential monogenic basis, e.g. those
with early onset (<50 years), positive family history, or atypical clinical presentation, with particular attention to those originating from less well studied (underrepresented) populations.
For patients, knowledge of one's genetic status can provide valuable
information regarding prognosis (likelihood
of developing, or passing on, the disease; disease course; etc.), which may be helpful in life planning. It also opens up the possibility of participating in clinical trials or benefiting from new genetics-based treatments.
Notably, all recruited patients will undergoextensive genotyping including testing for known mutations
in established Parkinson's disease genes (using the Genome Diversity Array, GDA),
and a large proportion will also undergo whole genome and/or long-read
sequencing.
For clinicians and researchers,
this project provides a great opportunity to better understand the genetic architecture of PD in their respective
communities/countries, in addition
to opportunities for scientific collaborations and joint publications
and grants.
of developing, or passing on, the disease; disease course; etc.), which may be helpful in life planning. It also opens up the possibility of participating in clinical trials or benefiting from new genetics-based treatments.
Notably, all recruited patients will undergoextensive genotyping including testing for known mutations
in established Parkinson's disease genes (using the Genome Diversity Array, GDA),
and a large proportion will also undergo whole genome and/or long-read
sequencing.
For clinicians and researchers,
this project provides a great opportunity to better understand the genetic architecture of PD in their respective
communities/countries, in addition
to opportunities for scientific collaborations and joint publications
and grants.
What
are the benefits
of contributing cases/families?
are the benefits
of contributing cases/families?
We encourage the submission of both patients
without a genetic diagnosis
and those already known to carry pathogenic variants in Parkinson's disease genes .
To submit a patient/family, go to
and those already known to carry pathogenic variants in Parkinson's disease genes .
To submit a patient/family, go to
What are the benefits
of contributing cases/families?
of contributing cases/families?
For clinicians and researchers, this project provides
a great opportunity to better understand
the genetic architecture of PD in their respective
communities/countries, in addition to opportunities
for scientific collaborations and joint publications
and grants.
We encourage the submission of both patients without
a genetic diagnosis and those already known to carry pathogenic variants in Parkinson's disease genes .
To submit a patient/family, go to
a great opportunity to better understand
the genetic architecture of PD in their respective
communities/countries, in addition to opportunities
for scientific collaborations and joint publications
and grants.
We encourage the submission of both patients without
a genetic diagnosis and those already known to carry pathogenic variants in Parkinson's disease genes .
To submit a patient/family, go to
What are the benefits
of contributing cases/families?
of contributing cases/families?
For clinicians and researchers, this project provides
a great opportunity to better understand
the genetic architecture of PD in their respective
communities/countries, in addition to opportunities
for scientific collaborations and joint publications
and grants.
We encourage the submission of both patients without a genetic diagnosis and those already known to carry pathogenic variants in Parkinson's disease genes.
To submit a patient/family, go to
a great opportunity to better understand
the genetic architecture of PD in their respective
communities/countries, in addition to opportunities
for scientific collaborations and joint publications
and grants.
We encourage the submission of both patients without a genetic diagnosis and those already known to carry pathogenic variants in Parkinson's disease genes.
To submit a patient/family, go to
